Published in Mol Immunol on August 01, 2004
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog (2009) 5.82
Very few substitutions in a germ line antibody are required to initiate significant domain exchange. J Virol (2010) 1.41
Immunogenicity of the outer domain of a HIV-1 clade C gp120. Retrovirology (2007) 1.13
Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency. J Virol (2008) 1.11
A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120. FASEB J (2008) 0.86
Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1. J Biol Chem (2009) 0.85
Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120. J Gen Virol (2008) 0.84
2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies. J Virol (2012) 0.83
A strategy for phage display selection of functional domain-exchanged immunoglobulin scaffolds with high affinity for glycan targets. J Immunol Methods (2011) 0.79
Global shape and ligand binding efficiency of the HIV-1-neutralizing antibodies differ from those of antibodies that cannot neutralize HIV-1. J Biol Chem (2014) 0.78
Introduction of germline residues improves the stability of anti-HIV mAb 2G12-IgM. Biochim Biophys Acta (2015) 0.76
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol (2002) 6.11
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med (2005) 5.68
Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol (2004) 5.29
Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell (2012) 5.16
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity (2005) 4.26
Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature (2007) 4.12
Association between changes in air pollution levels during the Beijing Olympics and biomarkers of inflammation and thrombosis in healthy young adults. JAMA (2012) 3.52
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol (2006) 3.34
Histone H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation. Mol Cell (2008) 3.18
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J (2003) 2.81
Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4. Cardiovasc Res (2010) 2.77
A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology (2007) 2.66
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov (2013) 2.52
Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A (2005) 2.50
Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis (2004) 2.47
Cryo-EM study of the chromatin fiber reveals a double helix twisted by tetranucleosomal units. Science (2014) 2.37
Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics (2008) 2.26
Probing meiotic recombination and aneuploidy of single sperm cells by whole-genome sequencing. Science (2012) 2.14
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol (2002) 2.06
The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol (2004) 2.02
Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol (2007) 1.81
Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1beta and 18. J Gen Virol (2005) 1.78
The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int (2012) 1.77
A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology (2007) 1.74
IL-10 regulates murine lupus. J Immunol (2002) 1.70
Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol (2005) 1.68
Single-cell methylome landscapes of mouse embryonic stem cells and early embryos analyzed using reduced representation bisulfite sequencing. Genome Res (2013) 1.67
Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol (2004) 1.58
Engineering of Pichia pastoris for improved production of antibody fragments. Biotechnol Bioeng (2006) 1.58
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol (2007) 1.56
Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS (2003) 1.55
In planta protein sialylation through overexpression of the respective mammalian pathway. J Biol Chem (2010) 1.52
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature (2016) 1.52
Identification of a novel biomarker gene set with sensitivity and specificity for distinguishing between allograft rejection and tolerance. Liver Transpl (2012) 1.49
Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous beta1,4-galactosylated N-glycan profile. J Biol Chem (2009) 1.49
HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol Cancer Res (2007) 1.48
Computational fluid dynamics for investigation of saliva pressure in parotid obstruction. Laryngoscope (2012) 1.47
Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry (2007) 1.46
Cardiorespiratory biomarker responses in healthy young adults to drastic air quality changes surrounding the 2008 Beijing Olympics. Res Rep Health Eff Inst (2013) 1.45
Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J Virol (2003) 1.45
HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology (2009) 1.45
Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology (2004) 1.45
Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS (2007) 1.44
Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J Virol (2004) 1.44
Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol (2004) 1.43
Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS (2006) 1.43
Prognostic value of plasma heart-type fatty acid-binding protein in patients with acute pulmonary embolism: a meta-analysis. Chest (2014) 1.43
Inflammatory and oxidative stress responses of healthy young adults to changes in air quality during the Beijing Olympics. Am J Respir Crit Care Med (2012) 1.42
The association study of plasma levels of pigment epithelium-derived factor with acute coronary syndrome in the chinese han population. Cardiology (2013) 1.41
Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey. Clin Rheumatol (2014) 1.41
Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol (2004) 1.40
hTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics. Am J Physiol Renal Physiol (2008) 1.40
Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus. Int J Rheum Dis (2013) 1.39
Crystal structure of HAb18G/CD147: implications for immunoglobulin superfamily homophilic adhesion. J Biol Chem (2008) 1.38
Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine (2009) 1.37
Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3⁺ regulatory T-cell responses in mice. Mol Med (2012) 1.37
Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol (2010) 1.36
Whole-genome analysis of 5-hydroxymethylcytosine and 5-methylcytosine at base resolution in the human brain. Genome Biol (2014) 1.36
Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern. Plant Biotechnol J (2007) 1.34
Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Res Hum Retroviruses (2006) 1.30
A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat Biotechnol (2005) 1.28
Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrob Agents Chemother (2006) 1.27
Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J Virol (2010) 1.24
Tomographic subvolume alignment and subvolume classification applied to myosin V and SIV envelope spikes. J Struct Biol (2008) 1.24
A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics (2009) 1.24
Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses (2004) 1.24
Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys (2006) 1.23
Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol (2009) 1.21
Cryo-EM structure of a transcribing cypovirus. Proc Natl Acad Sci U S A (2012) 1.20
In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J Virol (2007) 1.20
A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjögren's syndrome at 7q11.23. Nat Genet (2013) 1.19
Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. AIDS Res Hum Retroviruses (2008) 1.19
Role of the frequency of blood CD4(+) CXCR5(+) CCR6(+) T cells in autoimmunity in patients with Sjögren's syndrome. Biochem Biophys Res Commun (2012) 1.18
MimoDB 2.0: a mimotope database and beyond. Nucleic Acids Res (2011) 1.18
Gigaxonin interacts with tubulin folding cofactor B and controls its degradation through the ubiquitin-proteasome pathway. Curr Biol (2005) 1.18
Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS (2002) 1.17
Involvement of CD147 in overexpression of MMP-2 and MMP-9 and enhancement of invasive potential of PMA-differentiated THP-1. BMC Cell Biol (2005) 1.17
Structure of the Leanyer orthobunyavirus nucleoprotein-RNA complex reveals unique architecture for RNA encapsidation. Proc Natl Acad Sci U S A (2013) 1.17
Atomic model of a cypovirus built from cryo-EM structure provides insight into the mechanism of mRNA capping. Proc Natl Acad Sci U S A (2011) 1.17
The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12. Adv Exp Med Biol (2003) 1.15
H3.3 actively marks enhancers and primes gene transcription via opening higher-ordered chromatin. Genes Dev (2013) 1.14
Interaction of U-box E3 ligase SNEV with PSMB4, the beta7 subunit of the 20 S proteasome. Biochem J (2005) 1.14